Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.

PMID:
29859337
2.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

3.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
4.

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, Hollebecque A, Azaro A, Hervieu A, Rihawi K, De Marinis F.

Eur J Cancer. 2017 Dec;87:131-139. doi: 10.1016/j.ejca.2017.10.016. Epub 2017 Nov 14.

5.

Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2.

PMID:
29094232
6.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.

PMID:
28826074
7.

Cost analysis of adverse events associated with non-small cell lung cancer management in France.

Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E.

Clinicoecon Outcomes Res. 2017 Jul 27;9:443-449. doi: 10.2147/CEOR.S138963. eCollection 2017.

8.

Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.

Angevin E, Cassier PA, Italiano A, Gonçalves A, Gazzah A, Terret C, Toulmonde M, Gravis G, Varga A, Parlavecchio C, Paci A, Poinsignon V, Soria JC, Drubay D, Hollebecque A.

Eur J Cancer. 2017 Sep;83:194-202. doi: 10.1016/j.ejca.2017.06.036. Epub 2017 Jul 24.

PMID:
28750271
9.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP.

Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12.

PMID:
28618305
10.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

11.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C.

Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14.

12.

Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials.

Hollebecque A, Lanoy E, Troallen F, Soulat-Dufour L, Massard C, Bahleda R, Varga A, Gazzah A, Postel-Vinay S, Ribrag V, Deutsch E, Angevin E, Boccara F, Cohen A, Soria JC, Ederhy S.

Int J Cardiol. 2016 Jul 1;214:364-9. doi: 10.1016/j.ijcard.2016.04.010. Epub 2016 Apr 7.

PMID:
27085130
13.

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O.

Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Review.

PMID:
26765102
14.

Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?

Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC.

Ann Oncol. 2016 Feb;27(2):344-52. doi: 10.1093/annonc/mdv570. Epub 2015 Nov 23.

PMID:
26598538
15.

Isolation and characterization of renal cancer stem cells from patient-derived xenografts.

Hasmim M, Bruno S, Azzi S, Gallerne C, Michel JG, Chiabotto G, Lecoz V, Romei C, Spaggiari GM, Pezzolo A, Pistoia V, Angevin E, Gad S, Ferlicot S, Messai Y, Kieda C, Clay D, Sabatini F, Escudier B, Camussi G, Eid P, Azzarone B, Chouaib S.

Oncotarget. 2016 Mar 29;7(13):15507-24. doi: 10.18632/oncotarget.6266.

16.

Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience.

Helissey C, Biondani P, Roquet F, Lanoy E, Mir O, Varga A, Massard C, Gazzah A, Ribrag V, Bahleda R, Postel-Vinay S, Angevin E, Deutsch E, Soria JC, Hollebecque A.

Int J Cancer. 2016 Feb 15;138(4):875-80. doi: 10.1002/ijc.29849. Epub 2015 Oct 13.

17.

Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.

Kossai M, Duchemann B, Boutros C, Caramella C, Hollebecque A, Angevin E, Gazzah A, Bahleda R, Ileana E, Massard C, Vielh P, Soria JC, Besse B.

Lung Cancer. 2015 Sep;89(3):306-10. doi: 10.1016/j.lungcan.2015.06.014. Epub 2015 Jun 22.

PMID:
26160757
18.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

Deutsch E, Le Péchoux C, Faivre L, Rivera S, Tao Y, Pignon JP, Angokai M, Bahleda R, Deandreis D, Angevin E, Hennequin C, Besse B, Levy A, Soria JC.

Ann Oncol. 2015 Jun;26(6):1223-9. doi: 10.1093/annonc/mdv105. Epub 2015 Feb 20.

PMID:
25701455
19.

[Communication in the context of phase I clinical trials in oncology: implementation and evaluation of training programs].

Rouby P, Hollebecque A, Bahleda R, Deutsch E, Gomez-Rocca C, Angevin E, de La Motte Rouge T, Soria JC, Dauchy S.

Bull Cancer. 2015 Feb;102(2):174-81. doi: 10.1016/j.bulcan.2014.12.013. Epub 2015 Jan 15. French.

PMID:
25609484
20.

Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.

Escudier B, Grünwald V, Ravaud A, Ou YC, Castellano D, Lin CC, Gschwend JE, Harzstark A, Beall S, Pirotta N, Squires M, Shi M, Angevin E.

Clin Cancer Res. 2014 Jun 1;20(11):3012-22. doi: 10.1158/1078-0432.CCR-13-3006. Epub 2014 Apr 1.

21.

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings.

Bieche I, Vacher S, Vallerand D, Richon S, Hatem R, De Plater L, Dahmani A, Némati F, Angevin E, Marangoni E, Roman-Roman S, Decaudin D, Dangles-Marie V.

BMC Cancer. 2014 Mar 13;14:178. doi: 10.1186/1471-2407-14-178.

22.

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R.

Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21.

23.

Population pharmacokinetic/pharmacodynamic modeling to assist dosing schedule selection for dovitinib.

Wang X, Kay A, Anak O, Angevin E, Escudier B, Zhou W, Feng Y, Dugan M, Schran H.

J Clin Pharmacol. 2013 Jan;53(1):14-20. doi: 10.1177/0091270011433330. Epub 2013 Jan 24.

PMID:
23400739
24.

Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.

Angevin E, Lopez-Martin JA, Lin CC, Gschwend JE, Harzstark A, Castellano D, Soria JC, Sen P, Chang J, Shi M, Kay A, Escudier B.

Clin Cancer Res. 2013 Mar 1;19(5):1257-68. doi: 10.1158/1078-0432.CCR-12-2885. Epub 2013 Jan 21.

25.

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

Chargari C, Leteur C, Angevin E, Bashir T, Schoentjes B, Arts J, Janicot M, Bourhis J, Deutsch E.

Cancer Lett. 2011 Dec 22;312(2):209-18. doi: 10.1016/j.canlet.2011.08.011. Epub 2011 Aug 22.

PMID:
21937165
26.

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC.

Ann Oncol. 2012 May;23(5):1301-6. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14.

PMID:
21917737
27.

Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells.

Chargui J, Combaret V, Scaglione V, Iacono I, Péri V, Valteau-Couanet D, Dubrel M, Angevin E, Puisieux A, Romagne F, Bergeron C.

J Immunother. 2010 Jul-Aug;33(6):591-8. doi: 10.1097/CJI.0b013e3181dda207.

PMID:
20551838
28.

FGFR inhibitor induced peripheral neuropathy in patients with advanced RCC.

Loriot Y, Massard C, Angevin E, Lambotte O, Escudier B, Soria JC.

Ann Oncol. 2010 Jul;21(7):1559-60. doi: 10.1093/annonc/mdq237. Epub 2010 May 5. No abstract available.

PMID:
20444848
29.

Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma.

Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, Musat E, Sharma RN, Lienard D, Keilholz U, Testori A, Eggermont A, MacKie R, Robert C, Cook M, Thompson JF, Angevin E, Spatz A; European Organization for Research and Treatment of Cancer Melanoma Group.

Clin Cancer Res. 2007 Jul 1;13(13):3825-30.

30.

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Escudier B, Lassau N, Angevin E, Soria JC, Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel E, Armand JP, Robert C.

Clin Cancer Res. 2007 Mar 15;13(6):1801-9.

31.

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Escudier B, Dorval T, Chaput N, André F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L.

J Transl Med. 2005 Mar 2;3(1):10.

32.

Exosomes for cancer immunotherapy.

Andre F, Escudier B, Angevin E, Tursz T, Zitvogel L.

Ann Oncol. 2004;15 Suppl 4:iv141-4. Review. No abstract available.

PMID:
15477298
33.

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mécheri S, Tursz T, Zitvogel L.

J Clin Invest. 2004 Aug;114(3):379-88.

34.

IL-4 confers NK stimulatory capacity to murine dendritic cells: a signaling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules.

Terme M, Tomasello E, Maruyama K, Crépineau F, Chaput N, Flament C, Marolleau JP, Angevin E, Wagner EF, Salomon B, Lemonnier FA, Wakasugi H, Colonna M, Vivier E, Zitvogel L.

J Immunol. 2004 May 15;172(10):5957-66.

35.

Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma.

Movassagh M, Spatz A, Davoust J, Lebecque S, Romero P, Pittet M, Rimoldi D, Liénard D, Gugerli O, Ferradini L, Robert C, Avril MF, Zitvogel L, Angevin E.

Cancer Res. 2004 Mar 15;64(6):2192-8.

36.

Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients.

Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A.

Int J Cancer. 2004 Apr 10;109(3):393-401.

37.

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.

Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2137-46.

38.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

39.

Exosome-based immunotherapy.

Chaput N, Taïeb J, Schartz NE, André F, Angevin E, Zitvogel L.

Cancer Immunol Immunother. 2004 Mar;53(3):234-9. Epub 2004 Jan 16. Review.

PMID:
14727085
40.

[NK cell-based immunotherapy: new prospects and involvement of dendritic cells].

Borg C, Taieb J, Terme M, Maruyama K, Flament C, Angevin E, Zitvogel L.

Bull Cancer. 2003 Aug-Sep;90(8-9):699-705. Review. French.

41.

[Exosomes and anti-tumour immunotherapy].

Chaput N, Andre F, Schartz NE, Flament C, Angevin E, Escudier B, Zitvogel L.

Bull Cancer. 2003 Aug-Sep;90(8-9):695-8. French.

42.

Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.

Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB.

J Immunother. 2003 Sep-Oct;26(5):440-50.

PMID:
12973033
43.

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.

Griscelli F, Opolon P, Saulnier P, Mami-Chouaib F, Gautier E, Echchakir H, Angevin E, Le Chevalier T, Bataille V, Squiban P, Tursz T, Escudier B.

Gene Ther. 2003 Mar;10(5):386-95.

PMID:
12601393
44.

Tumor-derived exosomes: a new source of tumor rejection antigens.

André F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L.

Vaccine. 2002 Dec 19;20 Suppl 4:A28-31. Review.

PMID:
12477425
45.

Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.

Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Bénard J, Beaujean F, Boccaccio C, Zitvogel L, Angevin E.

Blood. 2002 Oct 1;100(7):2554-61.

46.

Phase II trial of thalidomide in renal-cell carcinoma.

Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A.

Ann Oncol. 2002 Jul;13(7):1029-35.

PMID:
12176780
47.

Malignant effusions and immunogenic tumour-derived exosomes.

Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L.

Lancet. 2002 Jul 27;360(9329):295-305.

PMID:
12147373
48.

In vivo-targeted gene delivery using antibody-based nonviral vector.

Déas O, Angevin E, Cherbonnier C, Senik A, Charpentier B, Levillain JP, Oosterwijk E, Hirsch F, Dürrbach A.

Hum Gene Ther. 2002 Jun 10;13(9):1101-14.

PMID:
12067443
49.

Thalidomide and venous thrombosis.

Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A.

Ann Intern Med. 2002 May 7;136(9):711. No abstract available.

PMID:
11992318
50.

Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk.

Fernandez NC, Flament C, Crépineau F, Angevin E, Vivier E, Zitvogel L.

Eur Cytokine Netw. 2002 Jan-Mar;13(1):17-27.

Supplemental Content

Loading ...
Support Center